610 related articles for article (PubMed ID: 14871964)
1. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
[TBL] [Abstract][Full Text] [Related]
2. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
3. Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.
Mimura K; Kono K; Southwood S; Fikes J; Takahashi A; Miyagawa N; Sugai H; Fujii H
Cancer Immunol Immunother; 2006 Nov; 55(11):1358-66. PubMed ID: 16435129
[TBL] [Abstract][Full Text] [Related]
4. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
[TBL] [Abstract][Full Text] [Related]
5. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay.
Akiyama Y; Komiyama M; Nakamura Y; Iizuka A; Oshita C; Kume A; Nogami M; Miyata H; Ashizawa T; Yoshikawa S; Kiyohara Y; Yamaguchi K
Cancer Immunol Immunother; 2012 Dec; 61(12):2311-9. PubMed ID: 22707303
[TBL] [Abstract][Full Text] [Related]
8. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen.
Zhu B; Chen Z; Cheng X; Lin Z; Guo J; Jia Z; Zou L; Wang Z; Hu Y; Wang D; Wu Y
Clin Cancer Res; 2003 May; 9(5):1850-7. PubMed ID: 12738743
[TBL] [Abstract][Full Text] [Related]
9. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
[TBL] [Abstract][Full Text] [Related]
10. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V
J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370
[TBL] [Abstract][Full Text] [Related]
11. Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.
Takedatsu H; Shichijo S; Katagiri K; Sawamizu H; Sata M; Itoh K
Clin Cancer Res; 2004 Feb; 10(3):1112-20. PubMed ID: 14871991
[TBL] [Abstract][Full Text] [Related]
12. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
[TBL] [Abstract][Full Text] [Related]
13. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE.
Miyahara Y; Naota H; Wang L; Hiasa A; Goto M; Watanabe M; Kitano S; Okumura S; Takemitsu T; Yuta A; Majima Y; Lemonnier FA; Boon T; Shiku H
Clin Cancer Res; 2005 Aug; 11(15):5581-9. PubMed ID: 16061876
[TBL] [Abstract][Full Text] [Related]
14. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
[TBL] [Abstract][Full Text] [Related]
15. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
[TBL] [Abstract][Full Text] [Related]
16. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
18. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
[TBL] [Abstract][Full Text] [Related]
19. Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
Kobayashi J; Torigoe T; Hirohashi Y; Idenoue S; Miyazaki A; Yamaguchi A; Hiratsuka H; Sato N
J Transl Med; 2009 Jan; 7():1. PubMed ID: 19123955
[TBL] [Abstract][Full Text] [Related]
20. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.
Eikawa S; Kakimi K; Isobe M; Kuzushima K; Luescher I; Ohue Y; Ikeuchi K; Uenaka A; Nishikawa H; Udono H; Oka M; Nakayama E
Int J Cancer; 2013 Jan; 132(2):345-54. PubMed ID: 22729530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
